XL-413

XL-413 is a small molecule inhibitor of cell division cycle 7 homolog (CDC7), a serine-threonine protein kinase that is essential for the initiation of DNA replication. It is currently under investigation for its potential use in the treatment of various cancers.

Mechanism of Action

XL-413 works by inhibiting the activity of CDC7, a protein kinase that plays a crucial role in the initiation of DNA replication. By blocking the function of CDC7, XL-413 prevents the replication of DNA, thereby inhibiting the proliferation of cancer cells.

Pharmacokinetics

The pharmacokinetics of XL-413 are currently under investigation. Preliminary studies suggest that it is well-absorbed and has a favorable bioavailability profile.

Clinical Trials

XL-413 is currently in the early stages of clinical development. Preclinical studies have shown promising results, with XL-413 demonstrating significant anti-tumor activity in various cancer cell lines.

Potential Therapeutic Applications

XL-413 has potential therapeutic applications in the treatment of a wide range of cancers, including breast cancer, lung cancer, and colorectal cancer. Further research is needed to fully elucidate its therapeutic potential.

Side Effects

As with all drugs, XL-413 has the potential to cause side effects. The most common side effects observed in preclinical studies include nausea, vomiting, and fatigue. However, these side effects are generally mild and manageable.

See Also

• Cell division cycle 7 homolog (CDC7)
• DNA replication
• Protein kinase
• Cancer
• Pharmacokinetics

References

<references/>

This article is a stub related to pharmacology. You can help WikiMD by expanding it!